Business Wire

Sofinnova Partners Raises €150M for Its Third Industrial Biotech Fund Dedicated to Environmental Impact

17.11.2021 09:00:00 EET | Business Wire | Press release

Share

Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today that it has raised €150 million in capital for its early-stage environmental impact fund, bringing the firm’s total assets under management to €2.5 billion across its platform of investment strategies. Sofinnova Industrial Biotech II is part of the venture capital firm’s pioneering sustainability strategy initiated over a decade ago with the launch of the Sofinnova Green Seed Fund.

The fund will continue to finance early-stage companies harnessing biotechnology to develop sustainable solutions across the food, agriculture, chemical and materials sectors. The current portfolio includes companies developing bio-based crop protection solutions (Biotalys, Micropep Technologies), upcycling agricultural waste into chemicals, food or feed ingredients (Afyren, Comet Bio), using fermentation to develop food ingredients (DMC Biotechnologies, Protera, Biosyntia, Microphyt) or biologically producing new chemicals and materials (DNA Script, EnginZyme).

Joško Bobanović, Partner in the Sofinnova Industrial Biotech Fund, said: “The fundraise attests to the success of our strategy over the past decade and the growing understanding of how biotech can help to address global environmental challenges such as climate change, biodiversity, pollution, and food waste. We are grateful for the confidence demonstrated by our investors, a large majority of whom are returning and a significant number of new investors joining from across the globe, reflecting the growing importance and prioritization of this sector.”

Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said: “Sofinnova is a leader across the life sciences value chain and we were one of the first to see early on the power of biotechnology to create sustainable solutions. We have one of the most accomplished VC teams in industrial biotech and are now more empowered to continue doing what we have been doing for 50 years: Partnering with exceptional entrepreneurs to transform groundbreaking science into the businesses of the future.”

About Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.

Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: www.sofinnovapartners.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:

B ommy Lee
Head of Communications, Sofinnova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11

North America
RooneyPartners LLC
Kate Barrette
kbarrette@rooneypartners.com
+1 212 223 0561

France
StrategiesImage
Anne Rein
anne.rein@strategiesimage.com
+33 (0) 6 03 35 92 05

Italy
Havas PR Milan
Marco Fusco
marco.fusco@havaspr.com
+39 (0) 345 6538145

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New AI Research from GFT Technologies: 84% of CIOs Have Canceled an AI Project Over Legacy System Limits29.9.2026 15:07:00 EEST | Press release

A new AI study from GFT Technologies, an AI-centric global digital transformation company, finds that legacy infrastructure is one of the biggest obstacles to enterprise AI success, with the vast majority of technology leaders reporting it has forced them to abandon AI initiatives. The GFT survey, conducted by Wakefield Research among 945 CIOs and CTOs across 19 countries at companies with at least $500M in annual revenue (fielded August 11-31, 2026), reveals that AI's promise and its risks are accelerating in tandem. Key themes include legacy infrastructure undermining AI initiatives, skepticism over AI's return on investment, geopolitical and regulatory uncertainty reshaping strategy, distrust of how companies explain workforce decisions, and rising personal risk for technology leaders. “AI adoption is moving quickly, but our research shows that enterprises are increasingly recognizing the importance of the foundation underneath it. For many organizations, legacy infrastructure is be

Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO ® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America29.9.2026 15:00:00 EEST | Press release

Kyowa Kirin International, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the signing of an exclusive distribution agreement with Knight Therapeutics (“Knight”) (TSX: GUD) for the distribution of mogamulizumab in select countries in Latin America. Under the terms of the agreement, Knight will be responsible for seeking the necessary regulatory approvals and commercialising mogamulizumab for mycosis fungoides (MF) and Sézary syndrome (SS), two subtypes of CTCL, a rare non-Hodgkin’s lymphoma, in Argentina, Brazil, Colombia and Mexico. Knight will hold exclusive distribution rights for the medicine in these markets. Kyowa Kirin and Knight’s collaboration aims to support CTCL patients and improve their access to innovative therapies in Latin America. Céline Rhême, Cluster General Manager, Emerging Growth Markets, Kyowa Kirin, commented: “CTCL is more common in this region than many realise, and further work is needed to identify unmet needs and

Heaviside Industries Awarded $99M IDIQ Contract to Provide MOTH Spectrum Analyzers to U.S. Army29.9.2026 15:00:00 EEST | Press release

Heaviside Industries, a builder of multi-domain precision munitions platforms, announced it has been awarded a $99 million firm-fixed-price, indefinite delivery, indefinite quantity (IDIQ) contract by the U.S. Army to deliver its MOTH radio frequency (RF) spectrum analyzers in support of the Army’s electromagnetic spectrum operations (EMSO) priorities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929455358/en/ The five-year contract was awarded by U.S. Army Contracting Command at Aberdeen Proving Ground, Maryland and includes system procurement, fielding, upgrades, and sustainment. As unmanned systems proliferate and adversaries increasingly exploit the electromagnetic spectrum, the Army requires EMSO capabilities that are scalable, adaptable, and rapidly fieldable to maintain an advantage in the spectrum. Heaviside’s MOTH meets this need with real-time, passive RF detection in a low size, weight, power, and cost system

Royal Yacht International Represents Buyer in Landmark 132M Lürssen as Founder Predicts: “The Billion-dollar Yacht Is Coming”29.9.2026 15:00:00 EEST | Press release

Royal Yacht International has announced PROJECT M, a fully custom 132-metre Lürssensuperyacht exceeding 6,000 GT. But for Royal Yacht International Founder and CEO Tommaso Chiabra, the project is less about size than what it represents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928365204/en/ Project M At the very top of the luxury market, the world’s most exceptional yachts are becoming increasingly difficult to reproduce. Only a small number of shipyards can execute projects of this scale. Construction takes years. Specialist capacity is finite. Build slots are scarce. And replacement cost can change dramatically between contract signing and delivery. “People look at purchase price. Sophisticated owners look at replacement value. What would somebody have to spend, and how long would they have to wait, to recreate your yacht when it is delivered?” For RYI, this is changing the role of the yacht broker. HUNDREDS OF MI

Create Apps Championship Winners Highlight Dubai’s Strength as a Base for Scaling Digital Businesses29.9.2026 14:49:00 EEST | Press release

Winners of past editions of Dubai Chamber of Digital Economy’s Create Apps Championship have highlighted how Dubai is helping entrepreneurs transform promising ideas into scalable digital ventures, with the championship playing a key role in supporting their growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929068961/en/ During Create Apps Championship 2025 (Photo: AETOSWire) Launched in 2023 as part of the ‘Create Apps in Dubai’ initiative, the championship supports participants through specialised training, mentorship, connections with investors and partners, and funding to develop and launch winning apps. Mariam Mohammed Almarri, Co-Founder of Boom, said: “A major milestone in our journey was participating in the Create Apps Championship, where Boom was recognised as ‘Dubai’s App of the Year 2025’ and ‘Most Impactful App’. This recognition enabled us to build Boom and transport it from an idea into a real product.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye